SILVER SPRING, Md., June 13, 2011 /PRNewswire-USNewswire/ —
Science, public health, and regulatory highlights from the U.S.
Food and Drug Administration. Information in this document
is designed for credentialed journalists. Release dates and times
for items are current as of June 13, 2011.
(Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO)
FDA News & Notes does not contain any regulatory or
enforcement actions due to legal limitations.
Meetings, Workshops and Congressional
Testimony:
Friday, 6/17 – The
Dermatologic and Ophthalmic Drugs Advisory Committee discusses
aflibercept ophthalmic solution, proposed trade name EYLEA, for
treatment of neovascular age-related macular degeneration (wet
AMD). 8 a.m., The Inn & Conference Center, University of
Maryland College, 3501 University Blvd. East, Adelphi, Md.
Press Office Contact: Erica Jefferson, 301-796-4988,
erica.jefferson@fda.hhs.gov
FDA Office of Public Affairs Contact
Information:
Call or email FDA Office of Public Affairs, 301-796-4540,
fdaopa@fda.hhs.gov
List of FDA press officers and beats
More Resources:
‘/>”/>
SOURCE
